• Scientists Discover a Cure for the Deadliest Strain of Tuberculosis

    5 monthes ago - By NY Times

    Once, a diagnosis of extensively drug-resistant TB meant quick death. A new drug regimen cures most patients in just months.
    Read more ...


  • FDA OKs 'Game Changer' Pretomanid for Highly Resistant TB

    5 monthes ago - By Medscape

    Pretomanid is only the third approved TB drug in 40 years. A pivotal study shows the oral drug regimen has a success rate of 89% and treatment takes 6 months instead of the current 2 years.
    FDA Approvals
    Read more ...


  • Pretomanid, first TB drug developed by non-profit, gets FDA approval for resistant infections

    5 monthes ago - By Healio

    The FDA has approved pretomanid - the first tuberculosis drug developed by a non-profit organization - as part of a three-drug regimen for the treatment of extensively drug-resistant TB, or XDR-TB, and other resistant forms of the disease.
    The combination of pretomanid, Sirturo and Zyvox has been shown to treat XDR-TB and other highly resistant forms of TB in 6 months, cutting down the current treatment time by at least 12 months.
    “In the United States, there are not too many patients that have XDR-TB, but there are some.
    Read more ...


  • FDA Plans AdCom Meeting on Vascepa, Pushing CVD Approval

    5 monthes ago - By Medscape

    Vascepa, a high-dose purified form of eicosapentaenoic acid, showed significant benefit on CV events in the REDUCE-IT study, but any approval date for this indication will now be extended.
    Medscape Medical News
    Read more ...


  • FDA approves TB pill that cures more hard-to treat patients

    5 monthes ago - By ABC News

    US regulators approve new TB drug that shortens and improves treatment for hardest-to-treat cases
    Read more ...


  • FDA approves new drug for specific type of highly treatment-resistant tuberculosis

    5 monthes ago - By News Medical

    The U.S. Food and Drug Administration today approved Pretomanid Tablets in combination with bedaquiline and linezolid for the treatment of a specific type of highly treatment-resistant tuberculosis of the lungs.
    Read more ...